22 . 01 .2026
Press release
IMCAS 2026: Galderma showcases the latest scientific advances behind the industry’s broadest injectable aesthetics portfolio
21 . 01 .2026
Press release
Galderma provides update on arbitration case regarding neuromodulator research and development partnership
14 . 01 .2026
Press release
TOXINS 2026: Clinical updates on Galderma’s leading neuromodulator portfolio further reinforce its leadership in Injectable Aesthetics
17 . 12 .2025
Press release
New published data confirms Nemluvio® (nemolizumab) can rapidly relieve itch and improve sleep in as early as two days in both atopic dermatitis and prurigo nodularis
11 . 12 .2025
News story
GAIN ASCENT Summit, our training program for emerging injectors, marks the end of GAIN's first decade
11 . 12 .2025
Press release
Galderma announces first patient enrollment in study to assess nemolizumab in adults with Chronic Pruritus of Unknown Origin
